Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria

PLoS Med. 2008 Nov 18;5(11):e227. doi: 10.1371/journal.pmed.0050227.

Abstract

Steffen Borrmann and colleagues discuss appropriate endpoints and their measurement during phase III trials of new antimalarial drugs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antimalarials / therapeutic use*
  • Clinical Trials, Phase III as Topic*
  • Drug Therapy, Combination
  • Humans
  • Malaria, Falciparum / drug therapy*
  • Malaria, Falciparum / mortality
  • Malaria, Falciparum / parasitology
  • Malaria, Falciparum / prevention & control
  • Plasmodium falciparum / drug effects
  • Secondary Prevention
  • Survival Analysis
  • Treatment Outcome

Substances

  • Antimalarials